durvalumab
astrazeneca
['durva', 'imfinzi', 'topaz1', 'astrazeneca']
#astrazeneca reported that #imfinzi (#durvalumab) plus #chemotherapy further improved overall survival benefit in advanced #biliarytractcancer in the #topaz1 phase iii trial, reducing the risk of death by 24% in additional follow-up #esmo22 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.